A worldwide survey to assess the current approach to the treatment of patients with cancer and venous thromboembolism

 

 Buy Article Permissions and Reprints

Summary

Low-molecular-weight heparin (LWMH) is recommended as the preferred anticoagulant treatment over vitamin K antagonists (VKA) for venous thromboembolism (VTE) in patients with cancer. However, there is uncertainty about the duration and dose of LMWH treatment. Therefore, we designed this multinational survey to assess the current approach to the treatment of patients with cancer and VTE. An electronic survey tool was used to disseminate a survey containing 49 questions on different aspects of the treatment of patients with cancer and VTE, among both thrombosis and non-thrombosis specialists. A total of 229 invitations were sent, and 141 completed the survey (60% of the total). Fifty-eight percent of the respondents were from Europe, 35% from the US and the remaining 7% from other countries. Respondent’s specialties included haematology (23%), oncology (18%), pulmonology (15%) and general internal medicine (15%). LMWH was indicated as the first choice for the long-term treatment by 82% of the respondents, of whom 60% used full therapeutic doses and 40% chose a dose reduction. When continuing anticoagulants after the long-term treatment period, 44% of respondents preferred LMWH, 10% VKA, while the remaining 45% chose per individual patient for either LMWH or VKA. In conclusion, we observed a relatively high observance rate of the guidelines with respect to the use of LMWH for the long-term treatment of VTE in cancer. In contrast, the dose of LMWH and the type of anticoagulant chosen after the initial 3–12 months varied substantially, probably reflecting the limited available evidence.

• References

• 1 Heit JA, O’Fallon WM, Petterson TM. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162: 1245-1248.
  CrossrefPubMedGoogle Scholar
• 2 Heit JA, Silverstein MD, Mohr DN. et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809-815.
  CrossrefPubMedGoogle Scholar
• 3 Levitan N, Dowlati A, Remick SC. et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine 1999; 78: 285-291.
  PubMedGoogle Scholar
• 4 Otten HM, Mathijssen J, ten Cate H. et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 2004; 164: 190-194.
  CrossrefPubMedGoogle Scholar
• 5 Büller HR, van Doormaal FF, van Sluis GL. et al. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007; 5 (Suppl. 01) 246-254.
  CrossrefPubMedGoogle Scholar
• 6 Khorana AA, Francis CW, Culakova E. et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632-634.
  CrossrefPubMedGoogle Scholar
• 7 Walshe LJ, Malak SF, Eagan J. et al. Complication rates among cancer patients with peripherally inserted central catheters. J Clin Oncol 2002; 20: 3276-3281.
  CrossrefPubMedGoogle Scholar
• 8 Ambrus JL, Ambrus CM, Mink IB. et al. Causes of death in cancer patients. J Med 1975; 6: 61-64.
  PubMedGoogle Scholar
• 9 Prandoni P, Lensing AW, Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
  CrossrefPubMedGoogle Scholar
• 10 Lee AY, Levine MN, Baker RI. et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
  CrossrefPubMedGoogle Scholar
• 11 Meyer G, Marjanovic Z, Valcke J. et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-1735.
  CrossrefPubMedGoogle Scholar
• 12 Deitcher SR, Kessler CM, Merli G. et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12: 389-396.
  CrossrefPubMedGoogle Scholar
• 13 Hull RD, Pineo GF, Brant RF. et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 1062-1072.
  CrossrefPubMedGoogle Scholar
• 14 Akl EA, Labedi N, Barba M. et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011; 6: CD006650
  PubMedGoogle Scholar
• 15 Hutten BA, Prins MH, Gent M. et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18: 3078-3083.
  CrossrefPubMedGoogle Scholar
• 16 Lyman GH, Khorana AA, Falanga A. et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
  CrossrefPubMedGoogle Scholar
• 17 Kearon C, Akl EA, Comerota AJ. et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e419S-e494S.
  CrossrefPubMedGoogle Scholar
• 18 Prandoni P. How I treat venous thromboembolism in patients with cancer. Blood 2005; 106: 4027-4033.
  CrossrefPubMedGoogle Scholar
• 19 den Exter PL, Hooijer J, Dekkers OM. et al. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 2011; 29: 2405-2409.
  CrossrefPubMedGoogle Scholar
• 20 Gardner MJ, Altman DG. Statistics with confidence – Confidence intervals and statistical guidelines. Br Med J 1989; 17
  PubMedGoogle Scholar
• 21 Kakkar AK, Levine M, Pinedo HM. et al. Venous thrombosis in cancer patients: insights from the FRONTLINE survey.. Oncologist 2003; 8: 381-388.
  CrossrefPubMedGoogle Scholar
• 22 Kirwan CC, Nath E, Byrne GJ. et al. Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey.. Br Med J 2003; 327: 597-598.
  CrossrefPubMedGoogle Scholar
• 23 Johnson TP, Wislar JS.. Response rates and nonresponse errors in surveys.. J Am Med Assoc 2012; 307: 1805-1806.
  CrossrefPubMedGoogle Scholar
• 24 Palareti G, Legnani C, Lee A. et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy.. Thromb Haemost 2000; 84: 805-810.
  Article in Thieme ConnectPubMedGoogle Scholar
• 25 Kamphuisen P.. Longheva study.. Available at: http://clinicaltrials.gov/ct2/show/NCT01164046. Accessed July 16, 2012.
  PubMedGoogle Scholar
• 26 Schulman S.. Registry on recurrent VTE in cancer.. Available at http://www.isth.org/default/index.cfm/publications/registries-databases/recurrent-venousthromboembolism/ Accessed July 16, 2012.
  PubMedGoogle Scholar
• 27 van Doormaal FF, Raskob GE, Davidson BL. et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.. Thromb Haemost 2009; 101: 762-769.
  Article in Thieme ConnectPubMedGoogle Scholar
• 28 van Doormaal FF, Cohen AT, Davidson BL. et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial.. Thromb Haemost 2010; 104: 86-91.
  Article in Thieme ConnectPubMedGoogle Scholar
• 29 Sponsor Daiichi Sankyo Inc. Hokusai trial registration record.. Available at: http://clinicaltrials.gov/ct2/show/NCT00986154. Accessed July 16, 2012.
  PubMedGoogle Scholar
• 30 Kovacs MJ, Kahn SR, Rodger M. et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study).. J Thromb Haemost 2007; 5: 1650-1653.
  CrossrefPubMedGoogle Scholar
• 31 Savage KJ, Wells PS, Schulz V. et al. Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity.. Thromb Haemost 1999; 82: 1008-1010.
  Article in Thieme ConnectPubMedGoogle Scholar
• 32 Rathbun SW, Stoner JA, Whitsett TL.. Treatment of upper-extremity deep vein thrombosis.. J Thromb Haemost 2011; 9: 1924-1930.
  CrossrefPubMedGoogle Scholar
• 33 Cronin CG, Lohan DG, Keane M. et al. Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT.. AJR Am J Roentgenol 2007; 189: 162-170.
  CrossrefPubMedGoogle Scholar
• 34 Di Nisio M, Ferrante N, De Tursi M. et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy.. Thromb Haemost 2010; 104: 1049-1054.
  Article in Thieme ConnectPubMedGoogle Scholar

• Supplementary Material